Mechanistically, compound <b>A</b> targets HSP27, disrupts the HSP27-AR complex, and thereby promotes AR degradation in GBM cells at 1 μM, leading to inhibition of AR-overexpressing GBM cell growth with IC<sub>50</sub>s around 0.2 μM. The gene discussed is AR; the disease is glioblastoma.